Trial
NCT02671955
A Study of Safety, Pharmacokinetics, Pharmacodynamics of JNJ-61610588 in Participants With Advanced Cancer
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Janssen Research & Development, LLC
Collaborators
—
Condition
Advanced Cancer
Intervention
JNJ-61610588
Why stopped
Janssen business decision
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2018-03-27